2066 related articles for article (PubMed ID: 30312761)
21. Second-generation compound for the modulation of utrophin in the therapy of DMD.
Guiraud S; Squire SE; Edwards B; Chen H; Burns DT; Shah N; Babbs A; Davies SG; Wynne GM; Russell AJ; Elsey D; Wilson FX; Tinsley JM; Davies KE
Hum Mol Genet; 2015 Aug; 24(15):4212-24. PubMed ID: 25935002
[TBL] [Abstract][Full Text] [Related]
22. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
[TBL] [Abstract][Full Text] [Related]
23. Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null mice.
Li D; Yue Y; Lai Y; Hakim CH; Duan D
J Pathol; 2011 Jan; 223(1):88-98. PubMed ID: 21125668
[TBL] [Abstract][Full Text] [Related]
24. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
25. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
[TBL] [Abstract][Full Text] [Related]
26. TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice.
Call JA; Ervasti JM; Lowe DA
J Appl Physiol (1985); 2011 Jul; 111(1):200-5. PubMed ID: 21565990
[TBL] [Abstract][Full Text] [Related]
27. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice.
Li D; Long C; Yue Y; Duan D
Hum Mol Genet; 2009 Apr; 18(7):1209-20. PubMed ID: 19131360
[TBL] [Abstract][Full Text] [Related]
28. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
[TBL] [Abstract][Full Text] [Related]
29. Functional substitution by TAT-utrophin in dystrophin-deficient mice.
Sonnemann KJ; Heun-Johnson H; Turner AJ; Baltgalvis KA; Lowe DA; Ervasti JM
PLoS Med; 2009 May; 6(5):e1000083. PubMed ID: 19478831
[TBL] [Abstract][Full Text] [Related]
30. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
[TBL] [Abstract][Full Text] [Related]
31. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice.
Whitehead NP; Pham C; Gervasio OL; Allen DG
J Physiol; 2008 Apr; 586(7):2003-14. PubMed ID: 18258657
[TBL] [Abstract][Full Text] [Related]
32. Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in
Chan AS; Hardee JP; Blank M; Cho EH; McGregor NE; Sims NA; Lynch GS
J Appl Physiol (1985); 2023 Jul; 135(1):77-87. PubMed ID: 37262103
[TBL] [Abstract][Full Text] [Related]
33. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins.
Nelson DM; Lindsay A; Judge LM; Duan D; Chamberlain JS; Lowe DA; Ervasti JM
Hum Mol Genet; 2018 Jun; 27(12):2090-2100. PubMed ID: 29618008
[TBL] [Abstract][Full Text] [Related]
34. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
[TBL] [Abstract][Full Text] [Related]
35. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin S Contributes to the Pathogenesis of Muscular Dystrophy in Mice.
Tjondrokoesoemo A; Schips TG; Sargent MA; Vanhoutte D; Kanisicak O; Prasad V; Lin SC; Maillet M; Molkentin JD
J Biol Chem; 2016 May; 291(19):9920-8. PubMed ID: 26966179
[TBL] [Abstract][Full Text] [Related]
37. Integrative effects of dystrophin loss on metabolic function of the mdx mouse.
Strakova J; Kamdar F; Kulhanek D; Razzoli M; Garry DJ; Ervasti JM; Bartolomucci A; Townsend D
Sci Rep; 2018 Sep; 8(1):13624. PubMed ID: 30206270
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
39. SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models.
Mázala DA; Pratt SJP; Chen D; Molkentin JD; Lovering RM; Chin ER
Am J Physiol Cell Physiol; 2015 May; 308(9):C699-709. PubMed ID: 25652448
[TBL] [Abstract][Full Text] [Related]
40. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
